Earth Science Tech, Inc. (OTC Pink: ETST) is focused on research and development of high-grade industrial CBD oil nutraceuticals. Shares of the high-grade CBD company are climbing 18.45%, through afternoon trading on Thursday, May 4, 2017. Over the past month, Earth Science Tech, Inc. has seen average daily volume of 29,680 shares. However, volume of 95,237 shares or dollar volume of $116,189, has already exchanged hands on Thursday.
Shares of Earth Science Tech, Inc. are rallying today, after the company announced accomplishments and updates on its CBD-based nutraceutical patent compounding. The company has continued to develop a solid, liquid, and semi-solid form of its CBD-based nutraceuticals. The team is able to continue changing the color and taste of their formula, thanks to two of Earth Science Tech, Inc.’s provisional U.S. patents. Here is the full press release detailing of the updates and accomplishments of the company’s CBD nutraceutical patent compounding:
Earth Science Tech, Inc. Press Release:
Hollywood, May 02, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices and it’s subsidiary Cannabis Therapeutics Inc. are proud to announce the achievements and updates on its CBD-based nutraceutical patent compound.
Dr. Aube Earth Science Tech’s CEO & CSO, meets with Dr. Domenico and his chemical engineer every Tuesday, at Smart Medicines and have been working on three formulas. The formulas are in a solid, liquid, and semi solid form. Out of all three forms ETST’s science team sees the semi solid formula’s potential as a huge success. The final product looks similar to regular mustard, but it’s a very special condiment that keeps all properties of full spectrum hemp oil.
Both the color and taste of the formula can be changed with ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 along with other food coloring and natural flavors. It’s formulated with high industrial hemp CBD oil (30%) and CBD concentration, and can be packaged in a tube to be consumed directly as it is (half a tea spoon 3 times/day) as a nutraceutical product.
The product can keep the same texture and inert ingredients as the nutraceutical product but, with modulations of the amount of hemp oil (between 5% and 30%), and can be sold as a functional food, a condiment to flavor everyday food, as well as a dietary supplement.
For distinction between functional foods, nutraceuticals, and dietary supplements you can read this paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750935/
Text from the paper:
“Thus, nutraceuticals (as per the proposed definition)
differ from dietary supplements in the following aspects:
Nutraceuticals must not only supplement the diet
but should also aid in the prevention and/or treatment
of disease and/or disorder.
CONCLUSION When a functional food aids in the prevention
and/or treatment of disease(s) and/or disorder(s) (except anemia),
it is called a nutraceutical. The proposed definition can help form
distinction between functional foods, nutraceuticals, and dietary
There is no rule for the nutraceutical products. We can claim that our product is a nutraceutical and ongoing research.
In conclusion, we have the first nutraceutical formula with ETST’s U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST’s U.S. Provisional Application No. 62/102,538, filed January 12, 2015 nearly ready to apply to get a natural product number (NPN is mandatory to get license to sale in Canada) and FDA approval (Federal Food, Drug, and Cosmetic Act).
Dr. Aube stated, “I’m very proud and happy with our Science team achieving such great formulas and reaching closer to finalizing our three planned compounds. We look to be on track from our March 6, 2017 announcement and look forward on sharing more updates as we continue progressing. We plan on sharing our first video on our Cannabis Therapeutics along with many photos to share with our investors our profession very soon as well as finalizing Earth Science Pharmaceutical website that looks to be finalized within May.”
Nickolas S. Tabraue ETST’s President & COO updates the market, “We are still on track to release our highly anticipated, world-first High Grade Hemp CBD Strawberry Orange Blossom, Pet CBD, and our new edible line in mid-May as mentioned on April 20, 2017. Bottling and packaging look to commence during the first week of May and we plan on showing images on our new products and packaging very soon. Our Chief Sales Officer, Gabriel Aviles, has been receiving endless pre-order requests on our new line and we are on pace to have a record breaking month. Aside from our new products, packaging, and positive revenue forecast, we are looking to finalize a few major breakthroughs I will be excited to share when we have something more concrete in place. We greatly appreciate our loyal stakeholders’ support and look forward on showing the public where all the support has taken us, and what it has helped us build.”
ETST continuously plans on updating its shareholders on the above mentioned studies and new products as further progress and development occurs.
About Earth Science Tech, Inc. (ETST):
Earth Science Tech, Inc. has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world’s best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To find out more information on all our research please visit our website: www.earthsciencetech.com
ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST’s primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be “food based” and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 “Cannabinoids as antioxidants and neuroprotectants.” ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.
About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com
The accuracy of the MSN-2 medical device for the diagnosis of women with Chlamydia has already been proven via a study of 510 female patients, which showed PCR testing results on paired samples to be identical for 493 (96.6%) of the 510 women. To view this study, visit Evaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women.
About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com
Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson’ s Disease, Alzheimer’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. The 3 cannabis cannabinoid-based nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.